Cholinergic drugs play a pivotal role in pharmacodynamics by modulating the activity of the neurotransmitter acetylcholine within the body's cholinergic system. These drugs exert their effects by interacting with cholinergic receptors, namely muscarinic and nicotinic receptors. Muscarinic receptors are predominantly found in various organs, including the heart, smooth muscles, and glands, while nicotinic receptors are present in the neuromuscular junctions. Stimulation of muscarinic receptors by cholinergic drugs leads to diverse physiological responses, such as increased glandular secretion, smooth muscle contraction, and a decrease in heart rate. On the other hand, activation of nicotinic receptors results in neuromuscular transmission and subsequent skeletal muscle contraction. Pharmacodynamics of cholinergic drugs involve mimicking or enhancing the effects of acetylcholine, ultimately influencing processes like gastrointestinal motility, respiratory function, and cardiovascular regulation. Understanding these pharmacological dynamics is crucial for therapeutic applications, such as in the treatment of conditions like myasthenia gravis or for promoting gastrointestinal motility after surgery. However, careful consideration is required due to potential side effects, including bradycardia, bronchoconstriction, and gastrointestinal disturbances.
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Advancing EGFR-targeting macrocyclic peptide-drug conjugates to target KRAS-mutant solid tumors: Design, synthesis, and preclinical evaluations
Akash Panja, Ariel University, Israel